Wegovy (semaglutide) and Mounjaro (tirzepatide) have completely transformed the landscape of weight management and diabetes care. If you have been following the headlines, you already know these medications help people lose a significant amount of weight.
While they have a lot in common—and are often mentioned in the same breath—they are not identical. From their active ingredients to their FDA-approved uses, understanding the differences between these two powerhouse treatments is vital for finding the right fit for your health goals.
Here are the 8 key differences between Wegovy and Mounjaro.
1. They Have Different FDA-Approved Uses
The biggest difference between Wegovy and Mounjaro lies in what they are officially prescribed to treat.
- Wegovy: Primarily a weight-loss medication. It is approved for chronic weight management in certain adults and adolescents. Recently, it also gained FDA approval to treat Metabolic dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease, in adults with moderate-to-advanced liver scarring.
- Mounjaro: Officially approved to treat Type 2 Diabetes in adults and children ages 10 and older.
Is Mounjaro approved for weight loss? No, Mounjaro itself is not approved for weight loss. However, its active ingredient, tirzepatide, is FDA-approved for weight loss under the brand name Zepbound.
2. Wegovy is Available as a Pill
Both medications are famous for being once-weekly injections. However, as of recent updates, Wegovy is also available as a once-daily oral tablet for adults. Studies suggest the pills and injections provide similar weight-loss results, making the tablet a great alternative if you dislike needles.
Note: The pill must be taken first thing in the morning with no more than 4 oz of plain water, and you must wait 30 minutes before eating or drinking anything else.
3. Approved Age Ranges Differ
These medications cater to slightly different age demographics based on clinical trials:
- Mounjaro: Approved for adults and children ages 10 and older (for Type 2 diabetes).
- Wegovy Injections: Approved for adults and adolescents ages 12 and older (for weight loss).
- Wegovy Pills: Approved for adults only.
4. They Mimic Different Gut Hormones
Both drugs work by mimicking incretins—gut hormones that signal your pancreas to release insulin, slow down digestion, and tell your brain you are full. However, they target different receptors.
- Wegovy (Semaglutide): Belongs to the GLP-1 receptor agonist class. It solely mimics the GLP-1 hormone.
- Mounjaro (Tirzepatide): Is a dual GIP/GLP-1 receptor agonist. By mimicking two hormones (GIP and GLP-1), it can sometimes manage blood sugar and appetite even more effectively than GLP-1 agonists alone.
5. Mounjaro Likely Causes More Weight Loss
While both drugs yield excellent results, clinical trials indicate that tirzepatide (Mounjaro/Zepbound) generally leads to greater weight reduction.
In trials, people taking the highest dose of Mounjaro (15 mg) lost an average of 15.7% of their body weight over 18 months. In a direct clinical comparison of people without diabetes, those taking Zepbound lost nearly 50% more weight than those taking Wegovy. However, Wegovy is actively seeking approval for a higher 7.2 mg dose, which may close this gap in the future.
6. Wegovy Has Proven Cardiovascular Benefits
If you have a history of heart issues, Wegovy might be the preferred choice. In a landmark clinical trial, Wegovy was shown to lower the risk of Major Adverse Cardiovascular Events (MACE)—such as heart attacks and strokes—by 20%.
Because of this, the FDA officially approved Wegovy for cardiovascular risk reduction in adults with heart disease who are overweight or obese. Mounjaro is currently seeking similar FDA approval for heart benefits, expected later in 2026.
7. Storage Instructions Vary Slightly
Proper storage ensures your medication remains effective:
- Wegovy Injections: Can be kept at room temperature (up to 86°F) for up to 28 days.
- Mounjaro Injections: Can be kept at room temperature for up to 21 days.
- Wegovy Pills: Should be stored at room temperature in their original bottle to protect them from moisture (do not put them in a daily pill organizer).
8. Insurance Coverage
Because they are approved for different conditions, insurance coverage varies wildly. Your plan might completely deny Wegovy for weight loss but approve it if you have a history of heart disease or MASH. Conversely, your plan might readily cover Mounjaro, but only if you have a documented diagnosis of Type 2 diabetes. Always check your specific formulary.
Can You Combine or Switch Them?
Do not combine them. Because they work so similarly, taking Wegovy and Mounjaro together will drastically increase your risk of severe gastrointestinal side effects like nausea, vomiting, and diarrhea.
If you want to switch from one to the other (e.g., to break a weight-loss plateau), you must do so under strict medical supervision. Your doctor will likely start you on a lower dose of the new medication to help your body adjust.
The Bottom Line
Both Wegovy and Mounjaro are highly effective, but they serve different primary purposes. Wegovy (semaglutide) is your go-to for FDA-approved weight loss and cardiovascular protection. Mounjaro (tirzepatide) is a powerful tool for Type 2 diabetes management that also happens to trigger profound weight loss.
Also Read : 7 Tips to Help Keep You Healthy as You Age
